Publications Activation of FXR Restores Expression of Genes Dysregulated in Human IBD and Suppresses TNFα and IL-6 Signaling Pathways in Adoptive Transfer Colitis ModelEuropean Crohn’s and Colitis Organisation (ECCO) Virtual Congress, July 2021Read MoreFXR agonists for NASH: How are they different and what difference do they make?Journey of Hepatology, July 2021Read MoreCombination of FXR Agonist MET642 With Tofacitinib Exhibits Synergistic Effects in Improving Colitis in Adoptive T-Cell Transfer IBD ModelPoster presentation at DDW – Digestive Disease Week, May 2021Read MoreA structurally optimized FXR agonist, MET409, reduced liver fat content over 12 weeks in patients with non-alcoholic steatohepatitisJourney of Hepatology, February 2021Read MoreMET642, FXR Agonist with a Unique Chemotype, Demonstrates a Safe, Sustained Profile in a 14-Day Randomized Study in Healthy SubjectsPoster Presentation at NASH-TAG March 2021Read MoreChange in liver fat content at 4 weeks accurately predicts change in liver fat content at 12 weeks in non-alcoholic steatohepatitis patients treated with an FXR agonist: Analysis from a 12-week, randomized, placebo-controlled study with MET409Poster Presentation at AASLD The Liver Meeting Digital Experience, November 2020Read MoreDose-Dependent Changes in the Pharmacokinetic and Pharmacodynamic Profiles of MET409, a Sustained FXR Agonist, in Patients with NASHPoster Presentation at AASLD The Liver Meeting Digital Experience, November 2020Read MoreMET409, a Sustained FXR Agonist, Decreased Liver Fat and Improved Liver Chemistries in 12 Weeks in Patients with Nonalcoholic SteatohepatitisPoster Presentation at EASL - The International Liver Congress, August 2020Read MoreMET409, a Sustained FXR Agonist, Demonstrating Best-in-Class Potential for NASHPodium Presentation at Third Global NASH Congress, February 2020Read MoreMET409, a Sustained FXR Agonist, Decreased Hepatic Fat and Improved Liver Function without Raising LDL C after 28 Days in NASH PatientsPoster Presentation at AASLD Liver Meeting, November 2019Read MoreSustained FXR agonist M480 shows superior efficacy to THRb agonist MGL-3196 in reversing NASH and advanced fibrosisPoster Presentation at AASLD Liver Meeting, November 2019Read MoreMET409, a Sustained FXR Agonist, Decreased Hepatic Fat and Improved Liver Function without Raising LDL-C after 28 Days in NASH PatientsPoster Presentation at Paris NASH Meeting, July 2019Read MoreFXR Agonists with Sustained Activity Exhibit Efficacy Comparable to Anti-Il-12P40 In Treating Colitis Induced by Adoptive T-Cell TransferPoster presentation at DDW – Digestive Disease Week, May 2019Read MoreFXR Agonist M480, Exhibits Efficacy in Multiple Models of Inflammatory Bowel Disease (IBD) by Increasing Expression of Anti-Microbial Genes and Reducing Inflammatory Cytokine Expression in the GutPoster presentation at DDW – Digestive Disease Week, May 2019Read MoreMET409, an Optimized Sustained FXR Agonist, Was Safe and Well-Tolerated in a 14-Day Phase 1 Study in Healthy SubjectsPoster presentation at EASL – The International Liver Congress, April 2019Read MoreMET409 a potent, non-bile acid sustained FXR agonist, shows rapid disease reversal in a diet-induced obese model of biopsy-confirmed NASHPoster presentation at AASLD – The Liver Meeting, November 2018Read MoreTreatment response of murine sclerosing cholangitis to systemic versus intestinal FXR agonists segregates with their effects on hepatic pro-inflammatory cytokine productionOral presentation at AASLD – The Liver Meeting, November 2018Read MoreTreatment response of murine sclerosing cholangitis to systemic versus intestinal FXR agonists segregates with their effects on hepatic pro-inflammatory cytokine productionOral presentation at XXV International Bile Acid Meeting: Bile Acids in Health and Disease, July 2018Read MoreM480, an oral FXR agonist, is superior to Cyclosporine A and equally efficacious as anti-IL12/23 in the adoptive T-cell transfer model of IBD colitisOral presentation at Digestive Disease Week, June 2018 Read MoreSex disparity in response of murine sclerosing cholangitis to short-term treatment with FXR agonistsPoster presentation at AASLD – The Liver Meeting, October 2017 Read MoreEfficacy of the FXR agonist, MET 409, in male and female mouse models of NASH and fibrosisPoster presentation at AASLD – The Liver Meeting, October 2017Read MoreEfficacy of MET409, a potent, novel, non-bile acid FXR agonist, in rodents and cynomolgus monkeysPoster presentation at AASLD – The Liver Meeting, October 2017Read MoreFXR agonists with systemic rather than intestinal selective exposure are more efficacious in a diet-induced obese NASH mouse modelOral presentation at EASL – The International Liver Congress, April 2017Read MoreM480, a novel non-bile acid FXR agonist, shows improvement across multiple parameters in a diet-induced obese mouse model with biopsy confirmed NASHPoster presentation at EASL – The International Liver Congress, April 2017Read MoreComparison of M480 and PX-102, two non-bile acid FXR agonists from different chemical scaffolds, in a diet-induced obese mouse model with biopsy confirmed NASHPoster presentation at AASLD Emerging Trends in Non-Alcohoic Fatty Liver Disease Conference, March 2017Read More